LPTN Key Stats
|Revenue (Quarterly YoY Growth)||79.86%|
|EPS Diluted (TTM)||-0.5248|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-6.811M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-99.17%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- LPATH, INC Files SEC form 10-Q, Quarterly Report Nov 8
- MLV & Co. Starts Lpath Inc (LPTN) at Buy Street Insider Nov 5
- Lpath initiated with a Buy at MLV & Co. Nov 5
- Coverage initiated on Lpath by MLV & Co Nov 4
- Unusual 11 Mid-Day Movers 10/09: (MW) (VISN) (URRE) Higher; (ARIA) (LRN) LPTN) Lower Street Insider Oct 9
- Pre-Open Stock Movers 10/9: (MW) (CALD) (MG) Higher; (ARIA) (LRN) (PWRD) Lower (more...) Street Insider Oct 9
- After-Hours Stock Movers 10/8: (CALD) (MG) (AA) Higher; (LPTN) (YUM) (TKMR) Lower (more...) Street Insider Oct 8
- Lpath retains Agility Clinical to serve as its primary CRO Oct 8
- Lpath (LPTN) Reports Pfizer (PFE) to Divest Assets; Proposes to Sell iSONEP Street Insider Oct 8
- LPATH, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 8
LPTN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Lpath is down 30.03% over the last year vs S&P 500 Total Return up 30.02%, CytRx up 26.26%, and Ariad Pharmaceuticals down 78.15%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for LPTN
Pro Strategies Featuring LPTN
Did Lpath make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Lpath, Inc., is a biotechnology company focused on the discovery and development of lipidomic-based therapeutic antibodies. It has two product candidates that are currently in clinical development, and one in pre-clinical evaluation.